局部治疗联合免疫检查点抑制剂改善复发/转移性鼻咽癌生存
该回顾性研究纳入223例复发或转移性鼻咽癌患者,其中106例单用免疫检查点抑制剂(ICI),117例接受局部治疗联合ICI(LOCI)。经倾向性评分匹配和逆概率加权校正后,LOCI组无进展生存期(PFS)显著优于ICI组(中位PFS 30.53个月 vs 16.77个月,HR 0.524,95%CI 0.339-0.785,P=0.0014),亚组分析显示鼻咽/颈部复发、远处转移及寡转移患者均获益。
要点
- LOCI组中位PFS 30.53个月,显著优于单用ICI组的16.77个月。
- 鼻咽/颈部复发患者LOCI主要改善无远处转移生存(HR 0.437)。
- 寡转移(≤3个病灶)患者LOCI同样显著改善PFS(HR 0.458)。
核心结论
- 局部治疗联合ICI可显著改善复发或转移性鼻咽癌患者的无进展生存期。
研究设计与样本
- 回顾性纳入223例复发或转移性鼻咽癌患者,106例接受ICI单药,117例接受局部治疗联合ICI。
- 采用逆概率加权和倾向性评分匹配校正混杂因素,Kaplan-Meier法和Cox模型进行生存分析。
主要发现
- 中位随访32.93个月(范围22.23-46.37个月)。
- LOCI组中位PFS为30.53个月,ICI组为16.77个月(HR 0.524,95%CI 0.339-0.785,log-rank P=0.0014)。
- 鼻咽/颈部复发患者中,LOCI组改善PFS主要得益于无远处转移生存获益(HR 0.437,95%CI 0.193-0.987,P=0.0465)。
- 远处转移患者中,LOCI组PFS优于ICI组(HR 0.491,95%CI 0.289-0.834,P=0.0072)。
- 寡转移(≤3个病灶)患者中,LOCI组PFS获益(HR 0.458,95%CI 0.212-0.989,P=0.0416)。
临床怎么用
- 对于复发或转移性鼻咽癌患者,在ICI治疗基础上联合局部治疗可能改善PFS。
- 鼻咽/颈部复发、远处转移及寡转移患者均可考虑局部治疗联合ICI策略。
局限性
- 本研究为回顾性设计,存在选择偏倚可能。
- LOCI候选者的选择策略仍需进一步前瞻性研究探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The success of immunotherapy in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) necessitates a reassessment of local therapy as consolidation or salvage. This study aims to explore whether adding local therapy to immunotherapy can yield meaningful survival benefits for RM-NPC patients. PATIENTS AND METHODS: 223 patients diagnosed with RM-NPC were retrospectively included in the study. 106 received immune checkpoint inhibitor therapy (ICI) alone, and 117 received local therapy combined with ICI (LOCI). Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were further conducted to mitigate major clinically-relevant confounders. Kaplan-Meier method and Cox proportional hazards model were used to perform survival analyses and evaluate the prognostic factors. RESULTS: The median follow-up was 32.93 m (22.23-46.37 m). Patients receiving LOCI derived a significantly improved PFS when compared to the ICI group (median PFS, 30.53 m vs 16.77 m, HR, 0.524; 95%CI, 0.339-0.785; log-rank p = 0.0014). The PFS benefit remained after PSM and IPTW adjustment. In subgroup analysis, for patients with nasopharyngeal/nodal relapse (LRR-NPC), LOCI group achieved an improved PFS with a primary benefit in improving DMFS (HR, 0.437; 95%CI, 0.193-0.987; log-rank p = 0.0465) relative to the ICI group; and for patients with distant metastasis (DM-NPC), LOCI group also yielded a superior PFS (HR, 0.491; 95%CI, 0.289-0.834; log-rank p = 0.0072) than ICI group. Moreover, enhanced PFS was observed in LOCI group among patients with oligometastatic NPC (≤3 lesions) (HR, 0.458; 95%CI, 0.212-0.989; log-rank p = 0.0416). CONCLUSION: LOCI was associated with improved PFS in both recurrent and metachronous metastatic NPC patients. Strategies to select candidates for LOCI warrants further investigation.
引用
- Chen X, Zhu L, Chen J, et al. Local therapy to recurrent/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma. Eur J Cancer. 2026. PMID: 42721861. doi:10.1016/j.ejca.2026.117014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。